Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Has Average Price Target of $595.20 According to Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $602.27.

Several analysts have recently issued reports on the company. Truist Financial increased their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Finally, Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th.

Insider Buying and Selling at Medpace

In related news, CEO August Troendle sold 21,966 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the sale, the chief executive officer owned 338,225 shares in the company, valued at approximately $211,549,590.75. This trade represents a 6.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 336,140 shares of company stock worth $208,008,328. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. American Capital Management Inc. bought a new position in shares of Medpace during the second quarter worth about $111,329,000. Focus Partners Advisor Solutions LLC bought a new stake in Medpace in the second quarter valued at approximately $1,685,000. The Manufacturers Life Insurance Company acquired a new stake in Medpace during the 2nd quarter valued at approximately $10,615,000. California State Teachers Retirement System raised its holdings in Medpace by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the last quarter. Finally, Rice Hall James & Associates LLC bought a new position in Medpace during the 2nd quarter worth approximately $28,659,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Up 3.5%

NASDAQ MEDP opened at $620.51 on Tuesday. The company has a market cap of $17.32 billion, a price-to-earnings ratio of 36.37, a PEG ratio of 2.67 and a beta of 1.18. The company has a 50 day moving average of $600.57 and a 200-day moving average of $522.82. Medpace has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the business posted $3.10 earnings per share. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace will post 17.54 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.